|
|
Blood, 1 March 2005, Vol. 105, No. 5, pp. 1851-1861.
Prepublished online as a Blood First Edition Paper on November 18, 2004; DOI 10.1182/blood-2004-07-2947.
 Previous Article | Table of Contents | Next Article 
PLENARY PAPERS
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response
Stefano Monti,
Kerry J. Savage,
Jeffery L. Kutok,
Friedrich Feuerhake,
Paul Kurtin,
Martin Mihm,
Bingyan Wu,
Laura Pasqualucci,
Donna Neuberg,
Ricardo C. T. Aguiar,
Paola Dal Cin,
Christine Ladd,
Geraldine S. Pinkus,
Gilles Salles,
Nancy Lee Harris,
Riccardo Dalla-Favera,
Thomas M. Habermann,
Jon C. Aster,
Todd R. Golub, and
Margaret A. Shipp
From The Broad Institute, Cambridge, MA; the Department of Medical Oncology and the Department of Biostatistics, Dana-Farber Cancer Institute, Boston, MA; the Department of Pathology, Brigham and Women's Hospital, Boston, MA; the Department of Pathology and the Division of Hematology and Department of Medicine, Mayo Clinic, Rochester, MN; the Department of Pathology, Massachusetts General Hospital, Boston, MA; the Institute for Cancer Genetics, Columbia University, New York, NY; the Hematology Department, Centre Hospitalier Lyon-Sud, Lyon, France; and the Department of Pediatric Oncology, Dana-Farber Cancer Institute and Howard Hughes Medical Institute, Boston, MA.
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with recognized variability in clinical outcome, genetic features, and cells of origin. To date, transcriptional profiling has been used to highlight similarities between DLBCL tumor cells and normal B-cell subtypes and associate genes and pathways with unfavorable outcome. To identify robust and highly reproducible DL-BCL subtypes with comprehensive transcriptional signatures, we used a large series of newly diagnosed DLBCLs, whole genome arrays, and multiple clustering methods. Tumors were also analyzed for known common genetic abnormalities in DLBCL. There were 3 discrete subsets of DLBCL—"oxidative phosphorylation," "B-cell receptor/proliferation," and "host response" (HR)—identified characterized using gene set enrichment analysis and confirmed in an independent series. HR tumors had increased expression of T/natural killer cell receptor and activation pathway components, complement cascade members, macrophage/dendritic cell markers, and inflammatory mediators. HR DLB-CLs also contained significantly higher numbers of morphologically distinct CD2+/CD3+ tumor-infiltrating lymphocytes and interdigitating S100+/gamma interferon-induced lysosomal transferase–positive (GILT+) CD1a–/CD123– dendritic cells. The HR cluster shared features of histologically defined T-cell/histiocyte-rich B-cell lymphoma, including fewer genetic abnormalities, younger age at presentation, and frequent splenic and bone marrow involvement. These studies identify tumor microenvironment and host inflammatory response as defining features in DLBCL and suggest rational treatment targets in specific DLBCL subsets.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Profiling is a good thing (at least in the clinic)
- Pierluigi Porcu
Blood 2005 105: 1843.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
A. Chadburn, A. Chiu, J. Y. Lee, X. Chen, E. Hyjek, A. H. Banham, A. Noy, L. D. Kaplan, J. A. Sparano, K. Bhatia, et al.
Immunophenotypic Analysis of AIDS-Related Diffuse Large B-Cell Lymphoma and Clinical Implications in Patients From AIDS Malignancies Consortium Clinical Trials 010 and 034
J. Clin. Oncol.,
October 20, 2009;
27(30):
5039 - 5048.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Middendorp, Y. Xiao, J.-Y. Song, V. Peperzak, P. H. L. Krijger, H. Jacobs, and J. Borst
Mice deficient for CD137 ligand are predisposed to develop germinal center-derived B-cell lymphoma
Blood,
September 10, 2009;
114(11):
2280 - 2289.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Schoof, F. von Bonin, S. Zeynalova, M. Ziepert, W. Jung, M. Loeffler, M. Pfreundschuh, L. Trumper, and D. Kube
Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trial
Ann. Onc.,
September 1, 2009;
20(9):
1548 - 1554.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Li, S.-W. Kim, D. Rai, A. R. Bolla, S. Adhvaryu, M. C. Kinney, R. S. Robetorye, and R. C. T. Aguiar
Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma
Blood,
June 25, 2009;
113(26):
6681 - 6690.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-W. Kim, D. Rai, M. R. McKeller, and R. C. T. Aguiar
Rational combined targeting of phosphodiesterase 4B and SYK in DLBCL
Blood,
June 11, 2009;
113(24):
6153 - 6160.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Ci, J. M. Polo, L. Cerchietti, R. Shaknovich, L. Wang, S. N. Yang, K. Ye, P. Farinha, D. E. Horsman, R. D. Gascoyne, et al.
The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL
Blood,
May 28, 2009;
113(22):
5536 - 5548.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. C. Cerchietti, S. N. Yang, R. Shaknovich, K. Hatzi, J. M. Polo, A. Chadburn, S. F. Dowdy, and A. Melnick
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo
Blood,
April 9, 2009;
113(15):
3397 - 3405.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. I. Martin-Subero, M. Kreuz, M. Bibikova, S. Bentink, O. Ammerpohl, E. Wickham-Garcia, M. Rosolowski, J. Richter, L. Lopez-Serra, E. Ballestar, et al.
New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling
Blood,
March 12, 2009;
113(11):
2488 - 2497.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Ruan, K. Hajjar, S. Rafii, and J. P. Leonard
Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma
Ann. Onc.,
March 1, 2009;
20(3):
413 - 424.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D de Jong, W Xie, A Rosenwald, M Chhanabhai, P Gaulard, W Klapper, A Lee, B Sander, C Thorns, E Campo, et al.
Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium)
J. Clin. Pathol.,
February 1, 2009;
62(2):
128 - 138.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. Chng, E. D. Remstein, R. Fonseca, P. L. Bergsagel, J. A. Vrana, P. J. Kurtin, and A. Dogan
Gene expression profiling of pulmonary mucosa-associated lymphoid tissue lymphoma identifies new biologic insights with potential diagnostic and therapeutic applications
Blood,
January 15, 2009;
113(3):
635 - 645.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tuomisto, M. Sund, J. Tahkola, A. Latvanlehto, E.-R. Savolainen, H. Autio-Harmainen, A. Liakka, R. Sormunen, J. Vuoristo, A. West, et al.
A Mutant Collagen XIII Alters Intestinal Expression of Immune Response Genes and Predisposes Transgenic Mice to Develop B-Cell Lymphomas
Cancer Res.,
December 15, 2008;
68(24):
10324 - 10332.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. H. Coles, C. G.A. Marfella, A. N. Imbalzano, H. A. Steinman, D. S. Garlick, R. M. Gerstein, and S. N. Jones
p37Ing1b Regulates B-Cell Proliferation and Cooperates with p53 to Suppress Diffuse Large B-Cell Lymphomagenesis
Cancer Res.,
November 1, 2008;
68(21):
8705 - 8714.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mori, R. E. Rempel, J. T. Chang, G. Yao, A. S. Lagoo, A. Potti, A. Bild, and J. R. Nevins
Utilization of Pathway Signatures to Reveal Distinct Types of B Lymphoma in the E{micro}-myc Model and Human Diffuse Large B-Cell Lymphoma
Cancer Res.,
October 15, 2008;
68(20):
8525 - 8534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Byers
Blocks to paraffin get the CHOP, +R
Blood,
October 15, 2008;
112(8):
3006 - 3007.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Habermann, S. S. Wang, M. J. Maurer, L. M. Morton, C. F. Lynch, S. M. Ansell, P. Hartge, R. K. Severson, N. Rothman, S. Davis, et al.
Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era
Blood,
October 1, 2008;
112(7):
2694 - 2702.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Brune, E. Tiacci, I. Pfeil, C. Doring, S. Eckerle, C. J.M. van Noesel, W. Klapper, B. Falini, A. von Heydebreck, D. Metzler, et al.
Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis
J. Exp. Med.,
September 29, 2008;
205(10):
2251 - 2268.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Malumbres, J. Chen, R. Tibshirani, N. A. Johnson, L. H. Sehn, Y. Natkunam, J. Briones, R. Advani, J. M. Connors, G. E. Byrne, et al.
Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP
Blood,
June 15, 2008;
111(12):
5509 - 5514.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mittal, N. A. Marshall, L. Duncan, D. J. Culligan, R. N. Barker, and M. A. Vickers
Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma
Blood,
June 1, 2008;
111(11):
5359 - 5370.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Dierlamm, E. M. Murga Penas, S. Bentink, S. Wessendorf, H. Berger, M. Hummel, W. Klapper, D. Lenze, A. Rosenwald, E. Haralambieva, et al.
Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-cell lymphoma
Haematologica,
May 1, 2008;
93(5):
688 - 696.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Navarro, A. Gaya, A. Martinez, A. Urbano-Ispizua, A. Pons, O. Balague, B. Gel, P. Abrisqueta, A. Lopez-Guillermo, R. Artells, et al.
MicroRNA expression profiling in classic Hodgkin lymphoma
Blood,
March 1, 2008;
111(5):
2825 - 2832.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Chen, S. Monti, P. Juszczynski, J. Daley, W. Chen, T. E. Witzig, T. M. Habermann, J. L. Kutok, and M. A. Shipp
SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma
Blood,
February 15, 2008;
111(4):
2230 - 2237.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. B. Ding, J. J. Yu, R. Y.-L. Yu, L. M. Mendez, R. Shaknovich, Y. Zhang, G. Cattoretti, and B. H. Ye
Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas
Blood,
February 1, 2008;
111(3):
1515 - 1523.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. H. Young, D. D. Weisenburger, B. J. Dave, L. Smith, W. Sanger, J. Iqbal, E. Campo, J. Delabie, R. D. Gascoyne, G. Ott, et al.
Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma
Blood,
December 15, 2007;
110(13):
4396 - 4405.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.-C. Chang, G.-C. Huang, D. Jones, and Y.-H. Lin
Distribution Patterns of Dendritic Cells and T Cells in Diffuse Large B-Cell Lymphomas Correlate with Prognoses
Clin. Cancer Res.,
November 15, 2007;
13(22):
6666 - 6672.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Shin, S. Monti, D. J. Aires, M. Duvic, T. Golub, D. A. Jones, and T. S. Kupper
Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome
Blood,
October 15, 2007;
110(8):
3015 - 3027.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Parekh, J. M. Polo, R. Shaknovich, P. Juszczynski, P. Lev, S. M. Ranuncolo, Y. Yin, U. Klein, G. Cattoretti, R. D. Favera, et al.
BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms
Blood,
September 15, 2007;
110(6):
2067 - 2074.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. G. Mueller, C. Boix, W.-H. Kwan, C. Daussy, E. Fournier, W. H. Fridman, and T. J. Molina
Critical role of monocytes to support normal B cell and diffuse large B cell lymphoma survival and proliferation
J. Leukoc. Biol.,
September 1, 2007;
82(3):
567 - 575.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Lottaz, J. Toedling, and R. Spang
Annotation-based distance measures for patient subgroup discovery in clinical microarray studies
Bioinformatics,
September 1, 2007;
23(17):
2256 - 2264.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Juszczynski, J. Ouyang, S. Monti, S. J. Rodig, K. Takeyama, J. Abramson, W. Chen, J. L. Kutok, G. A. Rabinovich, and M. A. Shipp
The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma
PNAS,
August 7, 2007;
104(32):
13134 - 13139.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Plonquet, C Haioun, J-P Jais, A-L Debard, G Salles, M-C Bene, P Feugier, C Rabian, O Casasnovas, M Labalette, et al.
Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2 3 diffuse large B-cell lymphoma
Ann. Onc.,
July 1, 2007;
18(7):
1209 - 1215.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Chen, P. Ghosh, H. Osawa, C. Y. Sasaki, L. Rezanka, J. Yang, T. J. O'Farrell, and D. L. Longo
Resistance to TGF-{beta}1 correlates with aberrant expression of TGF-{beta} receptor II in human B-cell lymphoma cell lines
Blood,
June 15, 2007;
109(12):
5301 - 5307.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Zangani, M. Froyland, G. Y. Qiu, L. A. Meza-Zepeda, J. L. Kutok, K. M. Thompson, L. A. Munthe, and B. Bogen
Lymphomas can develop from B cells chronically helped by idiotype-specific T cells
J. Exp. Med.,
May 14, 2007;
204(5):
1181 - 1191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Robertson, B. S. Kahl, J. M. Vose, S. de Vos, M. Laughlin, P. J. Flynn, K. Rowland, J. C. Cruz, S. L. Goldberg, L. Musib, et al.
Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
J. Clin. Oncol.,
May 1, 2007;
25(13):
1741 - 1746.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Andreadis, P. A. Gimotty, P. Wahl, R. Hammond, J. Houldsworth, S. J. Schuster, and T. R. Rebbeck
Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma
Blood,
April 15, 2007;
109(8):
3409 - 3416.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-F. Qi, J. X. Zhou, C. H. Lee, Z. Naghashfar, S. Xiang, A. L. Kovalchuk, T. N. Fredrickson, J. W. Hartley, D. C. Roopenian, W. F. Davidson, et al.
Anaplastic, Plasmablastic, and Plasmacytic Plasmacytomas of Mice: Relationships to Human Plasma Cell Neoplasms and Late-Stage Differentiation of Normal B Cells
Cancer Res.,
March 15, 2007;
67(6):
2439 - 2447.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. de Jong, A. Rosenwald, M. Chhanabhai, P. Gaulard, W. Klapper, A. Lee, B. Sander, C. Thorns, E. Campo, T. Molina, et al.
Immunohistochemical Prognostic Markers in Diffuse Large B-Cell Lymphoma: Validation of Tissue Microarray As a Prerequisite for Broad Clinical Applications--A Study From the Lunenburg Lymphoma Biomarker Consortium
J. Clin. Oncol.,
March 1, 2007;
25(7):
805 - 812.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Polo, P. Juszczynski, S. Monti, L. Cerchietti, K. Ye, J. M. Greally, M. Shipp, and A. Melnick
Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas
PNAS,
February 27, 2007;
104(9):
3207 - 3212.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Lenburg, A. Sinha, D. V. Faller, and G. V. Denis
Tumor-specific and Proliferation-specific Gene Expression Typifies Murine Transgenic B Cell Lymphomagenesis
J. Biol. Chem.,
February 16, 2007;
282(7):
4803 - 4811.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J-M Andre, R Cimaz, B Ranchin, C Galambrun, Y Bertrand, R Bouvier, F Rieux-Laucat, M-C Trescol-Biemont, P Cochat, and N Bonnefoy-Berard
Overexpression of the antiapoptotic gene Bfl-1 in B cells from patients with familial systemic lupus erythematosus
Lupus,
February 1, 2007;
16(2):
95 - 100.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. N. Winter, E. A. Weller, S. J. Horning, and R. D. Gascoyne
Response: Outcomes with R-CHOP in DLBCL leave ample room for improvement
Blood,
January 15, 2007;
109(2):
844 - 844.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Shipp
Molecular Signatures Define New Rational Treatment Targets in Large B-Cell Lymphomas
Hematology,
January 1, 2007;
2007(1):
265 - 269.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Leseux, S. M. Hamdi, T. al Saati, F. Capilla, C. Recher, G. Laurent, and C. Bezombes
Syk-dependent mTOR activation in follicular lymphoma cells
Blood,
December 15, 2006;
108(13):
4156 - 4162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Alvaro, M. Lejeune, M.-T. Salvado, C. Lopez, J. Jaen, R. Bosch, and L. E. Pons
Immunohistochemical Patterns of Reactive Microenvironment Are Associated With Clinicobiologic Behavior in Follicular Lymphoma Patients
J. Clin. Oncol.,
December 1, 2006;
24(34):
5350 - 5357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Andreadis, P. Gimotty, R. Hammond, P. Wahl, J. Houldsworth, S. Schuster, and T. Rebbeck
Expression Levels of Glutathione Peroxidase 1 (GPx1) and Multi-Drug Resistance 1 (MDR1; ABCB1) Identify Patients with Diffuse Large B-Cell Lymphoma (DLBCL) That Have Superior Clinical Outcomes.
Blood (ASH Annual Meeting Abstracts),
November 16, 2006;
108(11):
839 - 839.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. B. Poulsen, R. Borup, N. Borregaard, F. C. Nielsen, M. B. Moller, and E. Ralfkiaer
Prognostic significance of metallothionein in B-cell lymphomas
Blood,
November 15, 2006;
108(10):
3514 - 3519.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Wang, J. R. Cerhan, P. Hartge, S. Davis, W. Cozen, R. K. Severson, N. Chatterjee, M. Yeager, S. J. Chanock, and N. Rothman
Common Genetic Variants in Proinflammatory and Other Immunoregulatory Genes and Risk for Non-Hodgkin Lymphoma
Cancer Res.,
October 1, 2006;
66(19):
9771 - 9780.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Barjaktarevic, A. Rahman, S. Radoja, B. Bogunovic, A. Vollmer, S. Vukmanovic, and M. Maric
Inhibitory Role of IFN-{gamma}-Inducible Lysosomal Thiol Reductase in T Cell Activation
J. Immunol.,
October 1, 2006;
177(7):
4369 - 4375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. R. Shen, D. O. Ferguson, M. Renard, K. K. Hoyer, U. Kim, X. Hao, F. W. Alt, R. G. Roeder, H. C. Morse III, and M. A. Teitell
Dysregulated TCL1 requires the germinal center and genome instability for mature B-cell transformation
Blood,
September 15, 2006;
108(6):
1991 - 1998.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Sanchez-Aguilera, C. Montalban, P. de la Cueva, L. Sanchez-Verde, M. M. Morente, M. Garcia-Cosio, J. Garcia-Larana, C. Bellas, M. Provencio, V. Romagosa, et al.
Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma
Blood,
July 15, 2006;
108(2):
662 - 668.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Juszczynski, J. L. Kutok, C. Li, J. Mitra, R. C. T. Aguiar, and M. A. Shipp
BAL1 and BBAP Are Regulated by a Gamma Interferon-Responsive Bidirectional Promoter and Are Overexpressed in Diffuse Large B-Cell Lymphomas with a Prominent Inflammatory Infiltrate.
Mol. Cell. Biol.,
July 1, 2006;
26(14):
5348 - 5359.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Bernal-Mizrachi, C. M. Lovly, and L. Ratner
The role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphomas
PNAS,
June 13, 2006;
103(24):
9220 - 9225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hummel, S. Bentink, H. Berger, W. Klapper, S. Wessendorf, T. F.E. Barth, H.-W. Bernd, S. B. Cogliatti, J. Dierlamm, A. C. Feller, et al.
A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.
N. Engl. J. Med.,
June 8, 2006;
354(23):
2419 - 2430.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Takahashi, F. Feuerhake, J. L. Kutok, S. Monti, P. Dal Cin, D. Neuberg, J. C. Aster, and M. A. Shipp
FAS Death Domain Deletions and Cellular FADD-like Interleukin 1{beta} Converting Enzyme Inhibitory Protein (Long) Overexpression: Alternative Mechanisms for Deregulating the Extrinsic Apoptotic Pathway in Diffuse Large B-Cell Lymphoma Subtypes.
Clin. Cancer Res.,
June 1, 2006;
12(11):
3265 - 3271.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. N. Winter, E. A. Weller, S. J. Horning, M. Krajewska, D. Variakojis, T. M. Habermann, R. I. Fisher, P. J. Kurtin, W. R. Macon, M. Chhanabhai, et al.
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study
Blood,
June 1, 2006;
107(11):
4207 - 4213.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. West, G. S. Ginsburg, A. T. Huang, and J. R. Nevins
Embracing the complexity of genomic data for personalized medicine.
Genome Res.,
May 1, 2006;
16(5):
559 - 566.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Booman, J. Douwes, A. M. Glas, S. A. Riemersma, E. S. Jordanova, K. Kok, A. Rosenwald, D. de Jong, E. Schuuring, and P. M. Kluin
Mechanisms and Effects of Loss of Human Leukocyte Antigen Class II Expression in Immune-Privileged Site-Associated B-Cell Lymphoma.
Clin. Cancer Res.,
May 1, 2006;
12(9):
2698 - 2705.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. P. Canellos
Introduction to a special series of unique entities within the spectrum of large-cell lymphoma.
Oncologist,
April 1, 2006;
11(4):
374 - 374.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Abramson
T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management.
Oncologist,
April 1, 2006;
11(4):
384 - 392.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Chen, J. Houldsworth, A. B. Olshen, G. Nanjangud, S. Chaganti, E. S. Venkatraman, J. Halaas, J. Teruya-Feldstein, A. D. Zelenetz, and R. S. K. Chaganti
Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas
Blood,
March 15, 2006;
107(6):
2477 - 2485.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-P. Bourquin, A. Subramanian, C. Langebrake, D. Reinhardt, O. Bernard, P. Ballerini, A. Baruchel, H. Cave, N. Dastugue, H. Hasle, et al.
Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling
PNAS,
February 28, 2006;
103(9):
3339 - 3344.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Pasqualucci, M. Compagno, J. Houldsworth, S. Monti, A. Grunn, S. V. Nandula, J. C. Aster, V. V. Murty, M. A. Shipp, and R. Dalla-Favera
Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma.
J. Exp. Med.,
February 20, 2006;
203(2):
311 - 317.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Takahashi, F. Feuerhake, S. Monti, J. L. Kutok, J. C. Aster, and M. A. Shipp
Lack of IKBA coding region mutations in primary mediastinal large B-cell lymphoma and the host response subtype of diffuse large B-cell lymphoma
Blood,
January 15, 2006;
107(2):
844 - 845.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Morton, S. S. Wang, S. S. Devesa, P. Hartge, D. D. Weisenburger, and M. S. Linet
Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001
Blood,
January 1, 2006;
107(1):
265 - 276.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Tedoldi, J. C. Paterson, M.-L. Hansmann, Y. Natkunam, T. Rudiger, P. Angelisova, M. Q. Du, H. Roberton, G. Roncador, L. Sanchez, et al.
Transmembrane adaptor molecules: a new category of lymphoid-cell markers
Blood,
January 1, 2006;
107(1):
213 - 221.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Takahashi, F. Feuerhake, J. L. Kutok, S. Monti, P. S. Dal Cin, D. Neuberg, J. C. Aster, and M. A. Shipp
FAS Death Domain Deletions and Increased c-FLIPlong Expression Occur in Different Subtypes of Diffuse Large B-Cell Lymphoma.
Blood (ASH Annual Meeting Abstracts),
November 16, 2005;
106(11):
416 - 416.
[Abstract]
|
|
|
|
|
|
|
I. S. Lossos
Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma
J. Clin. Oncol.,
September 10, 2005;
23(26):
6351 - 6357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. de Jong
Molecular Pathogenesis of Follicular Lymphoma: A Cross Talk of Genetic and Immunologic Factors
J. Clin. Oncol.,
September 10, 2005;
23(26):
6358 - 6363.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Abramson and M. A. Shipp
Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach
Blood,
August 15, 2005;
106(4):
1164 - 1174.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Feuerhake, J. L. Kutok, S. Monti, W. Chen, A. S. LaCasce, G. Cattoretti, P. Kurtin, G. S. Pinkus, L. de Leval, N. L. Harris, et al.
NF{kappa}B activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes
Blood,
August 15, 2005;
106(4):
1392 - 1399.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
